BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
- 16 December 2018
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 28 (2), 143-148
- https://doi.org/10.1080/13543784.2019.1558442
Abstract
Introduction: Approximately, 30.4–66.0% of cutaneous melanomas possess a mutation in the BRAF gene that activates downstream signaling through the mitogen-activated protein (MAP) kinase pathway; this provides an attractive target for the treatment of advanced melanoma. Although BRAF inhibitors rapidly suppress melanoma growth, median progression-free survival remains unsatisfactory. Recent clinical trials have investigated drugs that can optimally enhance and prolong the anti-melanoma effects of BRAF inhibitors. Area covered: This review discusses the development of BRAF inhibitor-based combination therapies for BRAF-mutant advanced melanoma. Expert opinion: Future strategies for the treatment of advanced melanoma include novel combination therapies using BRAF/MEK inhibitors and immune checkpoints inhibitors or histone deacetylase inhibitors. These combination therapies might enhance antitumor responses against melanoma, prolonging survival in advanced melanoma patients. Further clinical studies are needed to optimize these novel combination therapies.Keywords
Funding Information
- Japan Society for the Promotion of Science (16K10143)
This publication has 40 references indexed in Scilit:
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)Cancer Chemotherapy and Pharmacology, 2014
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint BlockadeCancer Immunology Research, 2014
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineAnnals Of Oncology, 2014
- A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populationsInvestigational New Drugs, 2014
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLCExpert Opinion on Drug Safety, 2013
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell CarcinomaClinical Cancer Research, 2006
- Mutations of the BRAF gene in human cancerNature, 2002